STAT
JUNE 17, 2024
Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceutical companies to delay the arrival of lower-cost generic medicines in the marketplace. In a bid to prevent the patent system from being abused, the U.S.
STAT
DECEMBER 4, 2024
Patent & Trademark Office has withdrawn a controversial proposal that was designed to prevent pharmaceutical companies from abusing the patent system.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 14, 2023
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers.
STAT
MARCH 21, 2023
government to remove the key negotiator working on a free trade agreement with the Indian government because of his previous ties to a major pharmaceutical company. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.
The Guardian - Pharmaceutical Industry
FEBRUARY 7, 2024
Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma India is known as the “ pharmacy of the world ”, supplying vital generic medicines at low prices to health services including the NHS. They spend billions on research and recoup billions.
pharmaphorum
DECEMBER 15, 2020
During this time, the role and responsibility of generics suppliers and manufacturers has been brought into stark perspective as one of the leading contributors in this industry-wide effort. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceutical companies.
European Pharmaceutical Review
FEBRUARY 26, 2024
Medicine indication extensions recommended by the CHMP The committee recommended extensions of indications for six EU-approved medicines, including: CARVYKTI ® ▼ (ciltacabtagene autoleucel; cilta-cel)* , Keytruda and Reblozyl*. These products were designated as an orphan medicine during their development.
Expert insights. Personalized for you.
118 
Let's personalize your content